Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Neoplasm
  • Immunoglobulin Fragments
  • Neoplasms, Experimental

abstract

  • Radium-223 in combination with docetaxel at the RP2D was well tolerated. Exploratory efficacy data suggested enhanced antitumour activity for the combination relative to docetaxel alone. Comparative studies with end-points of clinical benefit are warranted. ClinicalTrials.gov number: NCT01106352.

publication date

  • June 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2019.04.007

PubMed ID

  • 31082669

Additional Document Info

start page

  • 107

end page

  • 116

volume

  • 114